文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

临时经静脉膈神经刺激用于长期机械通气患者:RESCUE 1 可行性试验

Temporary Transvenous Diaphragmatic Neurostimulation in Prolonged Mechanically Ventilated Patients: A Feasibility Trial (RESCUE 1).
PubMed 文献 · Crit Care Explor · 2020-04-29
一句话结论多中心前瞻性开放标签单组可行性研究显示,经静脉膈神经刺激导管置入与撤除可行且安全,9例中7例达到成功脱机标准。

该多中心前瞻性开放标签单组可行性研究纳入机械通气≥7天且两次脱机试验失败的重症成人,在标准治疗基础上使用经静脉膈神经刺激导管进行临时膈肌神经刺激(最多每日三次)。主要结局为导管成功置入与撤除及安全应用神经刺激。11例符合全部入组标准(平均机械通气19.7天),9例导管置入成功,均成功标测一侧或双侧膈神经、治疗中显示膈肌收缩并成功撤除导管;9例中7例达到成功脱机标准。成功脱机者最大吸气压平均增加105%(平均变化19.7±17.9 cm H2O,p=0.03),快速浅呼吸指数平均改善44%(平均变化-63.5±64.4,p=0.04)。作者结论为该刺激系统可行且安全,随机临床试验正在进行中。

要点

  • 研究纳入机械通气≥7天且两次脱机试验失败的重症成人,平均机械通气时间19.7天。
  • 9例导管置入成功者均成功标测一侧或双侧膈神经、治疗中显示膈肌收缩并成功撤除导管。
  • 9例中7例达到成功脱机标准。
  • 成功脱机者最大吸气压平均变化19.7±17.9 cm H2O(p=0.03,平均增加105%)。
  • 成功脱机者快速浅呼吸指数平均变化-63.5±64.4(p=0.04,平均改善44%)。

适用人群与场景

  • 重症监护病房中机械通气≥7天且两次脱机试验失败的成人。

诊断标准与关键阈值

  • 入组条件:机械通气时间大于或等于7天,且已失败两次脱机试验。

处置流程与药物剂量

  • 在标准治疗基础上置入经静脉膈神经刺激导管,行经静脉膈肌神经刺激治疗,最多每日三次(tid)。
  • 刺激导管置入后标测一侧或双侧膈神经,确认治疗中膈肌收缩,治疗结束后撤除导管。

研究设计与关键结果

  • 多中心、前瞻性、开放标签、单组可行性研究;11例符合全部入组标准,平均机械通气时间19.7天。
  • 11例中9例导管置入成功;9例均成功标测一侧或双侧膈神经、治疗中显示膈肌收缩并成功撤除导管。
  • 9例中7例达到成功脱机标准。
  • 成功脱机者最大吸气压平均增加105%(平均变化19.7±17.9 cm H2O,p=0.03)。
  • 成功脱机者快速浅呼吸指数平均改善44%(平均变化-63.5±64.4,p=0.04)。

证据类型、等级与局限

  • 证据类型:多中心、前瞻性、开放标签、单组可行性研究。
  • 作者结论:经静脉膈肌神经刺激系统是刺激膈神经并诱导膈肌收缩的可行且安全的治疗方法;随机临床试验正在进行中,以将其与机械通气脱机的标准治疗进行比较。

对床旁实践的改变

  • 作者认为,经静脉膈肌神经刺激系统是刺激膈神经并诱导膈肌收缩的可行且安全的治疗方法;随机临床试验正在进行中,以将其与机械通气脱机的标准治疗进行比较。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Prolonged mechanical ventilation promotes diaphragmatic atrophy and weaning difficulty. The study uses a novel device containing a transvenous phrenic nerve stimulating catheter (Lungpacer IntraVenous Electrode Catheter) to stimulate the diaphragm in ventilated patients. We set out to determine the feasibility of temporary transvenous diaphragmatic neurostimulation using this device.

DESIGN: Multicenter, prospective open-label single group feasibility study.

SETTING: ICUs of tertiary care hospitals.

PATIENTS: Adults on mechanical ventilation for greater than or equal to 7 days that had failed two weaning trials.

INTERVENTIONS: Stimulation catheter insertion and transvenous diaphragmatic neurostimulation therapy up to tid, along with standard of care.

MEASUREMENTS AND MAIN RESULTS: Primary outcomes were successful insertion and removal of the catheter and safe application of transvenous diaphragmatic neurostimulation. Change in maximal inspiratory pressure and rapid shallow breathing index were also evaluated. Eleven patients met all entry criteria with a mean mechanical ventilation duration of 19.7 days; nine underwent successful catheter insertion. All nine had successful mapping of one or both phrenic nerves, demonstrated diaphragmatic contractions during therapy, and underwent successful catheter removal. Seven of nine met successful weaning criteria. Mean maximal inspiratory pressure increased by 105% in those successfully weaned (mean change 19.7 ± 17.9 cm H2O; p = 0.03), while mean rapid shallow breathing index improved by 44% (mean change -63.5 ± 64.4; p = 0.04).

CONCLUSIONS: The transvenous diaphragmatic neurostimulation system is a feasible and safe therapy to stimulate the phrenic nerves and induce diaphragmatic contractions. Randomized clinical trials are underway to compare it to standard-of-care therapy for mechanical ventilation weaning.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Ataya A, Silverman EP, Bagchi A, et al. Temporary Transvenous Diaphragmatic Neurostimulation in Prolonged Mechanically Ventilated Patients: A Feasibility Trial (RESCUE 1). Crit Care Explor. 2020. PMID: 32426748. doi:10.1097/CCE.0000000000000106

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。